Harrow (HROW) Return on Capital Employed (2011 - 2026)
Harrow's (HROW) quarterly Return on Capital Employed came in at 6.18% in Q1 2026, up 380.0% year-on-year from 1.29% in Q1 2025, and down 42.26% quarter-over-quarter from 10.71% in Q4 2025.
Harrow (HROW) Return on Capital Employed (2011 - 2026) Analysis & Trends
Harrow's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.18% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 380.0% year-over-year to 6.18% in Q1 2026; TTM through Mar 2026 was 6.18%, a 380.0% increase from a year earlier, with the FY2025 full-year figure at 10.24%, up 684.0% from the prior year.
- Return on Capital Employed slipped to 6.18% in Q1 2026 per HROW's latest filing, from 10.71% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 13.62% in Q2 2025 and bottomed at 3.82% in Q3 2024.
- The 5-year median for Return on Capital Employed is 1.49% (2023), against an average of 2.45%.
- Across the five-year window, Return on Capital Employed plunged 1737 bps in 2022 and surged 1706 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 1.75% in 2022, then plunged by 90 bps to 0.17% in 2023, then soared by 1733 bps to 3.16% in 2024, then soared by 239 bps to 10.71% in 2025, then slumped by 42 bps to 6.18% in 2026.
- Per Business Quant, the three latest HROW Return on Capital Employed figures stand at 6.18% (Q1 2026), 10.71% (Q4 2025), and 9.64% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 6.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.18% |
| Dec 31, 2025 | 10.71% |
| Sep 30, 2025 | 9.64% |
| Jun 30, 2025 | 13.62% |
| Mar 31, 2025 | 2.38% |
| Dec 31, 2024 | 3.16% |
| Sep 30, 2024 | -3.82% |
| Jun 30, 2024 | -3.45% |
| Mar 31, 2024 | -2.94% |
| Dec 31, 2023 | 0.17% |
| Sep 30, 2023 | 1.49% |
| Jun 30, 2023 | 0.85% |
| Mar 31, 2023 | 0.61% |
| Dec 31, 2022 | 1.75% |
| Sep 30, 2022 | 2.42% |
| Jun 30, 2022 | -1.98% |
| Mar 31, 2022 | 0.90% |
| Dec 31, 2021 | 1.78% |
| Sep 30, 2021 | 6.35% |
| Jun 30, 2021 | 15.39% |